-
Something wrong with this record ?
Measurable Residual Disease and Fusion Partner Independently Predict Survival and Relapse Risk in Childhood KMT2A-Rearranged Acute Myeloid Leukemia: A Study by the International Berlin-Frankfurt-Münster Study Group
RE. van Weelderen, K. Klein, CJ. Harrison, Y. Jiang, J. Abrahamsson, N. Arad-Cohen, E. Bart-Delabesse, B. Buldini, B. De Moerloose, MN. Dworzak, S. Elitzur, JM. Fernández Navarro, RB. Gerbing, BF. Goemans, HA. de Groot-Kruseman, E. Guest, SY. Ha,...
Language English Country United States
Document type Journal Article, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural
Grant support
U10 CA180886
NCI NIH HHS - United States
NLK
Free Medical Journals
from 2004 to 1 year ago
Open Access Digital Library
from 1999-01-01
PubMed
36996387
DOI
10.1200/jco.22.02120
Knihovny.cz E-resources
- MeSH
- Leukemia, Myeloid, Acute * genetics therapy MeSH
- Child MeSH
- Transplantation, Homologous MeSH
- Humans MeSH
- Myeloproliferative Disorders * MeSH
- Prognosis MeSH
- Recurrence MeSH
- Neoplasm, Residual etiology MeSH
- Hematopoietic Stem Cell Transplantation * methods MeSH
- Check Tag
- Child MeSH
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Research Support, N.I.H., Extramural MeSH
PURPOSE: A previous study by the International Berlin-Frankfurt-Münster Study Group (I-BFM-SG) on childhood KMT2A-rearranged (KMT2A-r) AML demonstrated the prognostic value of the fusion partner. This I-BFM-SG study investigated the value of flow cytometry-based measurable residual disease (flow-MRD) and evaluated the benefit of allogeneic stem-cell transplantation (allo-SCT) in first complete remission (CR1) in this disease. METHODS: A total of 1,130 children with KMT2A-r AML, diagnosed between January 2005 and December 2016, were assigned to high-risk (n = 402; 35.6%) or non-high-risk (n = 728; 64.4%) fusion partner-based groups. Flow-MRD levels at both end of induction 1 (EOI1) and 2 (EOI2) were available for 456 patients and were considered negative (<0.1%) or positive (≥0.1%). End points were 5-year event-free survival (EFS), cumulative incidence of relapse (CIR), and overall survival (OS). RESULTS: The high-risk group had inferior EFS (30.3% high risk v 54.0% non-high risk; P < .0001), CIR (59.7% v 35.2%; P < .0001), and OS (49.2% v 70.5%; P < .0001). EOI2 MRD negativity was associated with superior EFS (n = 413; 47.6% MRD negativity v n = 43; 16.3% MRD positivity; P < .0001) and OS (n = 413; 66.0% v n = 43; 27.9%; P < .0001), and showed a trend toward lower CIR (n = 392; 46.1% v n = 26; 65.4%; P = .016). Similar results were obtained for patients with EOI2 MRD negativity within both risk groups, except that within the non-high-risk group, CIR was comparable with that of patients with EOI2 MRD positivity. Allo-SCT in CR1 only reduced CIR (hazard ratio, 0.5 [95% CI, 0.4 to 0.8]; P = .00096) within the high-risk group but did not improve OS. In multivariable analyses, EOI2 MRD positivity and high-risk group were independently associated with inferior EFS, CIR, and OS. CONCLUSION: EOI2 flow-MRD is an independent prognostic factor and should be included as risk stratification factor in childhood KMT2A-r AML. Treatment approaches other than allo-SCT in CR1 are needed to improve prognosis.
Children's Cancer Center National Center for Child Health and Development Tokyo Japan
Children's Mercy Kansas City Kansas City MO
DCOG Dutch Childhood Oncology Group Utrecht the Netherlands
Department of Clinical Sciences Pediatrics Umeå University Umeå Sweden
Department of Oncology St Jude Children's Research Hospital Memphis TN
Department of Pediatric Hematology and Oncology Aghia Sophia Children's Hospital Athens Greece
Department of Pediatric Hematology and Oncology University Hospital Essen Essen Germany
Department of Pediatric Oncology Erasmus MC Sophia Children's Hospital Rotterdam the Netherlands
Department of Pediatrics and Adolescent Medicine Hong Kong Children's Hospital Kowloon Hong Kong
Department of Pediatrics Osaka University Graduate School of Medicine Suita Japan
Department of Statistics The Children's Oncology Group Monrovia California
IUC Toulouse Oncopole Laboratoire d'Hématologie secteur Génétique des Hémopathies Toulouse France
Pediatric Hematology and Oncology Department Hôpital Armand Trousseau Paris France
Pediatric Oncohematology Unit Hospital Universitari i Politècnic la Fe Valencia Spain
Pediatrics and Adolescent Medicine Aarhus University Hospital Aarhus Denmark
Princess Máxima Center for Pediatric Oncology Utrecht the Netherlands
Wilhelmina Children's Hospital University Medical Center Utrecht Utrecht the Netherlands
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23011234
- 003
- CZ-PrNML
- 005
- 20230801132908.0
- 007
- ta
- 008
- 230718s2023 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1200/JCO.22.02120 $2 doi
- 035 __
- $a (PubMed)36996387
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a van Weelderen, Romy E $u Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands $u Pediatric Oncology, Emma Children's Hospital, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands $1 https://orcid.org/0000000184855126
- 245 10
- $a Measurable Residual Disease and Fusion Partner Independently Predict Survival and Relapse Risk in Childhood KMT2A-Rearranged Acute Myeloid Leukemia: A Study by the International Berlin-Frankfurt-Münster Study Group / $c RE. van Weelderen, K. Klein, CJ. Harrison, Y. Jiang, J. Abrahamsson, N. Arad-Cohen, E. Bart-Delabesse, B. Buldini, B. De Moerloose, MN. Dworzak, S. Elitzur, JM. Fernández Navarro, RB. Gerbing, BF. Goemans, HA. de Groot-Kruseman, E. Guest, SY. Ha, H. Hasle, C. Kelaidi, H. Lapillonne, G. Leverger, F. Locatelli, R. Masetti, T. Miyamura, U. Norén-Nyström, S. Polychronopoulou, M. Rasche, JE. Rubnitz, J. Stary, A. Tierens, D. Tomizawa, CM. Zwaan, GJL. Kaspers
- 520 9_
- $a PURPOSE: A previous study by the International Berlin-Frankfurt-Münster Study Group (I-BFM-SG) on childhood KMT2A-rearranged (KMT2A-r) AML demonstrated the prognostic value of the fusion partner. This I-BFM-SG study investigated the value of flow cytometry-based measurable residual disease (flow-MRD) and evaluated the benefit of allogeneic stem-cell transplantation (allo-SCT) in first complete remission (CR1) in this disease. METHODS: A total of 1,130 children with KMT2A-r AML, diagnosed between January 2005 and December 2016, were assigned to high-risk (n = 402; 35.6%) or non-high-risk (n = 728; 64.4%) fusion partner-based groups. Flow-MRD levels at both end of induction 1 (EOI1) and 2 (EOI2) were available for 456 patients and were considered negative (<0.1%) or positive (≥0.1%). End points were 5-year event-free survival (EFS), cumulative incidence of relapse (CIR), and overall survival (OS). RESULTS: The high-risk group had inferior EFS (30.3% high risk v 54.0% non-high risk; P < .0001), CIR (59.7% v 35.2%; P < .0001), and OS (49.2% v 70.5%; P < .0001). EOI2 MRD negativity was associated with superior EFS (n = 413; 47.6% MRD negativity v n = 43; 16.3% MRD positivity; P < .0001) and OS (n = 413; 66.0% v n = 43; 27.9%; P < .0001), and showed a trend toward lower CIR (n = 392; 46.1% v n = 26; 65.4%; P = .016). Similar results were obtained for patients with EOI2 MRD negativity within both risk groups, except that within the non-high-risk group, CIR was comparable with that of patients with EOI2 MRD positivity. Allo-SCT in CR1 only reduced CIR (hazard ratio, 0.5 [95% CI, 0.4 to 0.8]; P = .00096) within the high-risk group but did not improve OS. In multivariable analyses, EOI2 MRD positivity and high-risk group were independently associated with inferior EFS, CIR, and OS. CONCLUSION: EOI2 flow-MRD is an independent prognostic factor and should be included as risk stratification factor in childhood KMT2A-r AML. Treatment approaches other than allo-SCT in CR1 are needed to improve prognosis.
- 650 _2
- $a dítě $7 D002648
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a homologní transplantace $7 D014184
- 650 12
- $a transplantace hematopoetických kmenových buněk $x metody $7 D018380
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a recidiva $7 D012008
- 650 12
- $a myeloproliferativní poruchy $7 D009196
- 650 _2
- $a reziduální nádor $x etiologie $7 D018365
- 650 12
- $a akutní myeloidní leukemie $x genetika $x terapie $7 D015470
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a Research Support, N.I.H., Extramural $7 D052061
- 700 1_
- $a Klein, Kim $u Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands $u Pediatric Oncology, Emma Children's Hospital, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands $u Wilhelmina Children's Hospital/University Medical Center Utrecht, Utrecht, the Netherlands $1 https://orcid.org/0000000297941071
- 700 1_
- $a Harrison, Christine J $u Leukemia Research Cytogenetics Group, Translational and Clinical Research Institute, Newcastle University Centre for Cancer, Newcastle-upon-Tyne, United Kingdom
- 700 1_
- $a Jiang, Yilin $u Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands
- 700 1_
- $a Abrahamsson, Jonas $u Department of Pediatrics, Institute of Clinical Sciences, Salgrenska University Hospital, Gothenburg, Sweden
- 700 1_
- $a Arad-Cohen, Nira $u Pediatric Hemato-Oncology Department, Ruth Rappaport Children's Hospital, Rambam Health Care Campus, Haifa, Israel
- 700 1_
- $a Bart-Delabesse, Emmanuelle $u IUC Toulouse-Oncopole, Laboratoire d'Hématologie secteur Génétique des Hémopathies, Toulouse, France
- 700 1_
- $a Buldini, Barbara $u Pediatric Hematology, Oncology and Stem Cell Transplant Division, Maternal and Child Health Department, Padua University, Padua, Italy $1 https://orcid.org/0000000172852390
- 700 1_
- $a De Moerloose, Barbara $u Department of Pediatric Hematology-Oncology and Stem Cell Transplantation, Ghent University Hospital, Ghent, Belgium $1 https://orcid.org/000000022449539X
- 700 1_
- $a Dworzak, Michael N $u St. Anna Children's Hospital, Department of Pediatrics, Medical University of Vienna, and St Anna Children's Cancer Research Institute, Vienna, Austria $1 https://orcid.org/0000000281751097
- 700 1_
- $a Elitzur, Sarah $u Department of Pediatric Hematology and Oncology, Schneider Children's Medical Center and Tel Aviv University, Tel Aviv, Israel $1 https://orcid.org/0000000234957578
- 700 1_
- $a Fernández Navarro, José M $u Pediatric Oncohematology Unit, Hospital Universitari i Politècnic la Fe, Valencia, Spain
- 700 1_
- $a Gerbing, Robert B $u Department of Statistics, The Children's Oncology Group, Monrovia, California
- 700 1_
- $a Goemans, Bianca F $u Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands $1 https://orcid.org/0000000340303228
- 700 1_
- $a de Groot-Kruseman, Hester A $u Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands $u DCOG, Dutch Childhood Oncology Group, Utrecht, the Netherlands
- 700 1_
- $a Guest, Erin $u Children's Mercy Kansas City, Kansas City, MO $1 https://orcid.org/0000000324825608
- 700 1_
- $a Ha, Shau-Yin $u Department of Pediatrics & Adolescent Medicine, Hong Kong Children's Hospital, Kowloon, Hong Kong $1 https://orcid.org/0000000291918743
- 700 1_
- $a Hasle, Henrik $u Pediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark $1 https://orcid.org/0000000339769231
- 700 1_
- $a Kelaidi, Charikleia $u Department of Pediatric Hematology and Oncology, Aghia Sophia Children's Hospital, Athens, Greece
- 700 1_
- $a Lapillonne, Hélène $u Pediatric Hematology and Oncology Department, Hôpital Armand Trousseau, Paris, France
- 700 1_
- $a Leverger, Guy $u Pediatric Hematology and Oncology Department, Hôpital Armand Trousseau, Paris, France
- 700 1_
- $a Locatelli, Franco $u Department of Pediatric Hematology and Oncology and Cell and Gene Therapy, IRCCS Ospedale Pediatrico Bambino Gesù, Catholic University of the Sacred Heart, Rome, Italy $1 https://orcid.org/0000000279763654
- 700 1_
- $a Masetti, Riccardo $u Pediatric Oncology and Hematology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, University of Bologna, Bologna, Italy $1 https://orcid.org/000000021264057X
- 700 1_
- $a Miyamura, Takako $u Department of Pediatrics, Osaka University Graduate School of Medicine, Suita, Japan $1 https://orcid.org/000000023226556X
- 700 1_
- $a Norén-Nyström, Ulrika $u Department of Clinical Sciences, Pediatrics, Umeå University, Umeå, Sweden $1 https://orcid.org/0000000156065442
- 700 1_
- $a Polychronopoulou, Sophia $u Department of Pediatric Hematology and Oncology, Aghia Sophia Children's Hospital, Athens, Greece
- 700 1_
- $a Rasche, Mareike $u Department of Pediatric Hematology and Oncology, University Hospital Essen, Essen, Germany $1 https://orcid.org/0000000276873655
- 700 1_
- $a Rubnitz, Jeffrey E $u Department of Oncology, St Jude Children's Research Hospital, Memphis, TN $1 https://orcid.org/0000000198853527
- 700 1_
- $a Stary, Jan $u Department of Pediatric Hematology and Oncology, University Hospital Motol and 2nd Faculty of Medicine, Charles University, Prague, Czech Republic $1 https://orcid.org/0000000268187743
- 700 1_
- $a Tierens, Anne $u Department of Pathobiology and Laboratory Medicine, University Health Network, Toronto General Hospital, Toronto, ON, Canada $1 https://orcid.org/0000000253508313
- 700 1_
- $a Tomizawa, Daisuke $u Children's Cancer Center, National Center for Child Health and Development, Tokyo, Japan
- 700 1_
- $a Zwaan, C Michel $u Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands $u Department of Pediatric Oncology, Erasmus MC-Sophia Children's Hospital, Rotterdam, the Netherlands $1 https://orcid.org/0000000168928268
- 700 1_
- $a Kaspers, Gertjan J L $u Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands $u Pediatric Oncology, Emma Children's Hospital, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands $1 https://orcid.org/0000000177168475
- 773 0_
- $w MED00002596 $t Journal of clinical oncology : official journal of the American Society of Clinical Oncology $x 1527-7755 $g Roč. 41, č. 16 (2023), s. 2963-2974
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36996387 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230718 $b ABA008
- 991 __
- $a 20230801132905 $b ABA008
- 999 __
- $a ok $b bmc $g 1963558 $s 1197499
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 41 $c 16 $d 2963-2974 $e 20230330 $i 1527-7755 $m Journal of clinical oncology $n J. clin. Oncol. $x MED00002596
- GRA __
- $a U10 CA180886 $p NCI NIH HHS $2 United States
- LZP __
- $a Pubmed-20230718
